Table 2 Clinical characteristics of the HNSCC samples in training, validation, whole sets
| Â | Training set (n = 300) | Validation set (n = 199) | Whole set (n = 499) |
|---|---|---|---|
Gender (%) | |||
 Male | 223 (74.3%) | 143 (71.9%) | 366 (73.3%) |
 Female | 77 (25.7) | 56 (28.1%) | 133 (26.7%) |
 Age (median, range) | 60 (19–900) | 61 (26–87) | 61 (19–90) |
Survival status | |||
 OS days (media, range) | 547(1–5252) | 580 (14–6417) | 558 (1–6417) |
 OS state (alive (%)/dead (%)) | 178 (59.3%)/122 (40.7%) | 126 (63.3%)/73 (36.7%) | 304 (60.9%)/195 (39.1%) |
Grade (%) | |||
 Grade1 | 44 (14.7%) | 17 (8.6%) | 61 (12.2%) |
 Grade2 | 180 (60.0%) | 118 (59.3%) | 298 (59.7%) |
 Grade3 | 67 (22.3%) | 52 (26.1%) | 119 (23.9%) |
 Grade4 | 2 (0.7%) | 0 (0.0%) | 2 (0.4%) |
 Unknown | 7 (2.3%) | 12 (6%) | 19 (3.8%) |
Stage (%) | |||
 I | 14 (4.7%) | 11 (5.5%) | 25 (5.0%) |
 II | 44 (14.7%) | 25 (12.6%) | 69 (13.8%) |
 III | 40 (13.3%) | 38 (19.1%) | 78 (15.7%) |
 IV | 160 (53.3%) | 99 (49.7%) | 259 (51.9%) |
 Unknown | 42 (14.0%) | 26 (13.1%) | 68 (13.6%) |
T (%) | |||
 0 | 1 (0.3%) | 0 (0.0%) | 1 (0.2%) |
 1 | 27 (9%) | 18 (9.0%) | 45 (9.0%) |
 2 | 72 (24.0%) | 59 (29.6%) | 131 (26.3%) |
 3 | 58 (19.3%) | 38 (19.1%) | 96 (19.2%) |
 4 | 110 (36.7%) | 61 (30.7%) | 171 (34.3%) |
 Unknown | 32 (10.7%) | 23 (11.6%) | 55 (11.0%) |
N (%) | |||
 0 | 104 (34.7%) | 66 (33.2%) | 170 (34.1%) |
 1 | 36 (12%) | 29 (14.6%) | 65 (13.0%) |
 2 | 103 (34.3%) | 61 (30.6%) | 164 (32.9%) |
 3 | 3 (1%) | 4 (2.0%) | 7 (1.4%) |
 Unknown | 54 (18%) | 39 (19.6%) | 93 (18.6%) |